| CAS ID: | 1132935-63-7 |
| Molecular Formula: | C26H27N3O5S |
| Molecular Weight: | 493.6 g/mol |
| Monoisotopic Mass: | 493.1671 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | DASABUVIR | ABT-333 | EXVIERA | DASABUVIR SODIUM |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31) | See All |
| InChI Key: | NBRBXGKOEOGLOI-UHFFFAOYSA-N | |
| Smiles: | COc1c(cc(cc1C(C)(C)C)N2C=CC(=O)NC2=O)c3ccc4cc(NS(=O)(=O)C)ccc4c3 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT02615145 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | November 26, 2015 | Last Verified | April 12, 2018 |
| Sponsor | AbbVie | ||
Trial Record 2
| ClinicalTrial ID | NCT02442284 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 13, 2015 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 3
| ClinicalTrial ID | NCT02219477 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | July 11, 2017 |
| Sponsor | AbbVie | ||
Trial Record 4
| ClinicalTrial ID | NCT02207088 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2014 | Last Verified | November 9, 2017 |
| Sponsor | AbbVie | ||
Trial Record 5
| ClinicalTrial ID | NCT01995071 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 26, 2013 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 6
| ClinicalTrial ID | NCT02517528 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 7, 2015 | Last Verified | October 8, 2018 |
| Sponsor | AbbVie | ||
Trial Record 7
| ClinicalTrial ID | NCT01704755 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 11, 2012 | Last Verified | October 19, 2015 |
| Sponsor | AbbVie (prior sponsor, Abbott) | ||
Trial Record 8
| ClinicalTrial ID | NCT02219503 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | June 29, 2016 |
| Sponsor | AbbVie | ||
Trial Record 9
| ClinicalTrial ID | NCT01939197 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | September 11, 2013 | Last Verified | November 17, 2017 |
| Sponsor | AbbVie | ||
Trial Record 10
| ClinicalTrial ID | NCT03053180 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | February 15, 2017 | Last Verified | March 14, 2019 |
| Sponsor | AbbVie | ||
Trial Record 11
| ClinicalTrial ID | NCT02640547 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 29, 2015 | Last Verified | October 17, 2018 |
| Sponsor | AbbVie | ||
Trial Record 12
| ClinicalTrial ID | NCT02636608 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 22, 2015 | Last Verified | May 30, 2018 |
| Sponsor | AbbVie | ||
| PubChem: | 56640146 |
| ChEMBL: | CHEMBL3137312 |